The Role of MEG in Assessment and Diagnosis In mTBI
MEGAbIT
MEGAbIT The Role of OPM MEG in Assessment and Diagnosis In mTBI. An Observational Study
2 other identifiers
observational
60
1 country
1
Brief Summary
Head injuries are responsible for 1.4 million visits to hospital each year in the United Kingdom (UK). Most patients are allowed home the same day and make a full recovery, but some will have persistent symptoms. The investigators aim to use the latest generation of imaging technology to investigate those with mild traumatic brain injury (mTBI) to better assess them. The investigators will invite patients presenting following trauma to the Emergency Department at Queen's Medical Centre, Nottingham, UK to participate. The investigators will compare those who have a suffered an mTBI to those who have non-head traumatic injuries. The investigators will use two magnetoencephalogram (MEG) systems and ultra-high field magnetic resonance imaging (MRI) to record the functioning and structure of the brain within days of participants' injury. The investigators will test memory and thinking skills, then follow participants for six months, record the severity of participants' symptoms, and find out who does not make a full recovery. Multimodal imaging will consist of a standard MEG device using Superconducting Quantum Interference Device (SQUID) sensors, a novel MEG device using Optically Pumped Magnetometer (OPM) sensors and seven Tesla MRI. The investigators will test whether these innovative imaging techniques are more sensitive to the acute damage that mTBI causes than routine imaging. The investigators will also test whether early imaging can reveal who is most seriously affected, identifying those who will not recover without additional support. It is currently not clear what the predominant mechanism of damage that causes these long-term problems is and the investigators hope this study will address this. The Medical Research Council is funding this work
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 25, 2019
CompletedFirst Posted
Study publicly available on registry
March 8, 2019
CompletedStudy Start
First participant enrolled
November 6, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 5, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 5, 2022
CompletedNovember 19, 2020
November 1, 2020
1.5 years
February 25, 2019
November 18, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Can mTBI participants be differentiated from non-head injured controls by measuring brain wave activity?
To measure and localize abnormal resting-state slow wave activity in an mTBI population in the acute stage (\< 2 weeks post injury). Voxel-wise source reconstruction of MEG resting state data using a beamforming approach will be used to generate a normative database of brain activity in the cohort of age and sex matched non-head injured trauma participants. The investigators will compare the oscillatory power in the theta and alpha frequency band between the mTBI cohort and the normative database to generate statistical maps of abnormal brain activity on a per participant basis. These will be assessed for statistically significant loci of abnormal slow wave power.
Within two weeks of injury
Secondary Outcomes (1)
Is the SQUID or OPM MEG system preferred by participants for tolerability and ease of use?
Within two weeks of injury
Other Outcomes (5)
What novel imaging measures best differentiate mTBI participants?
Assessment within two weeks of injury, follow up for six months
Does abnormal slow wave activity on MEG arise from areas with SWI or DTI abnormalities?
Assessment within two weeks of injury, follow up for six months
Does early imaging provide prognostic information?
Assessment within two weeks of injury, follow up for six months
- +2 more other outcomes
Study Arms (2)
mTBI cases
Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
Acute trauma controls
Non-head trauma controls matched for age and sex with the mTBI group
Interventions
All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
Eligibility Criteria
Potential participants will be identified form those attending the Emergency department of the Queen's Medical Centre, Nottingham
You may qualify if:
- Participant is willing and able to give informed consent for participation in the study
- Male or female, aged 18-35
- In the Investigator's opinion, is able and willing to comply with all study requirements.
- Willing to allow his or her General Practitioner to be notified of participation in the study
- Two groups will be recruited:
- Diagnosed by the clinical ED team with mTBI (without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
- Diagnosed by the clinical ED team with non-head trauma, matched for age and sex with the mTBI group.
You may not qualify if:
- Patient requiring hospitalisation for ≥24 hours at presentation
- Any contraindication to undergo 7T MRI scan
- Pregnancy
- Other neurological, developmental or psychiatric disorders e.g. brain tumour, stroke, epilepsy, Alzheimer disease, schizophrenia, post-traumatic stress disorder, major depressive disorder, bipolar disorder or history of learning disability
- Previous hospital attendance with TBI
- Substance or alcohol abuse within six months of enrolment
- Taking certain medications thought to alter MEG signals: opioids and synthetic opioids (excluding codeine and dihydrocodeine), anti-epileptic drugs, sedatives, neuroleptics, and hypnotics
- Extensive metal dental hardware e.g. braces and large metal dentures (excluding fillings), implanted medical devices or other metal objects in the head, neck, or face areas that although they hold no risk to participants during a MEG recording may cause non-removable artefacts in the MEG data.
- Participants who have participated in another research study involving an investigational product in the past 12 weeks.
- Any other significant disease or disorder, which, in the opinion of the Investigator, may put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Nottingham
Nottingham, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nikos Evangelou, MD
Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 25, 2019
First Posted
March 8, 2019
Study Start
November 6, 2019
Primary Completion
May 5, 2021
Study Completion
November 5, 2022
Last Updated
November 19, 2020
Record last verified: 2020-11